Meanwhile, the monotherapy of HDAC1 inhibitor such as romidepsin elevated serum CCL5 rather than intratumoral CCL5, in which the systemic administration increased serum CCL5 could potentially activate metastasis-prone CCR5+ tumor cells (51). Here, CCR5 is linked to neoplasm.